Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06300528
Title Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Narendranath Epperla
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.